You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results

 

Online download statistics by month:

Online download statistics by month: November 2020 to March 2024

AbstractFullPdf
Nov 2020356058
Dec 202031014
Jan 2021133052
Feb 2021174036
Mar 2021234083
Apr 2021182059
May 202155044
Jun 20210045
Jul 20210055
Aug 20210042
Sep 20210047
Oct 2021175055
Nov 2021220059
Dec 2021148041
Jan 2022238027
Feb 2022166030
Mar 2022290045
Apr 2022446057
May 2022258052
Jun 2022252042
Jul 2022324035
Aug 2022354039
Sep 2022226034
Oct 2022220023
Nov 2022264035
Dec 2022268015
Jan 2023238022
Feb 2023258026
Mar 2023284015
Apr 2023394030
May 2023356023
Jun 2023332022
Jul 2023246029
Aug 2023224019
Sep 2023318013
Oct 2023210030
Nov 2023270018
Dec 2023280021
Jan 2024154016
Feb 2024212014
Mar 2024218019
Total900801441